Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma

BACKGROUND: This study aimed to evaluate whether hypereosinophilia is a clinical biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma treated with nivolumab plus ipilimumab. METHODS: This was a retrospective cohort study conducted at Jichi Medical Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Hodaka, Washino, Satoshi, Suzuki, Daisuke, Saikawa, Rika, Tonezawa, Shiori, Hagiwara, Rie, Funazaki, Shunsuke, Yoshida, Masashi, Konishi, Tsuzumi, Saito, Kimitoshi, Miyagawa, Tomoaki, Hara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040214/
https://www.ncbi.nlm.nih.gov/pubmed/35468815
http://dx.doi.org/10.1186/s12902-022-01024-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040214/
https://www.ncbi.nlm.nih.gov/pubmed/35468815
http://dx.doi.org/10.1186/s12902-022-01024-4

Ejemplares similares